Point72 Asset Management
LIMNW

Point72 Asset Management’s Liminatus Pharma Warrants LIMNW Stock Holding History

Point72 Asset Management’s Portfolio LIMNW Stock Details LIMNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,400
Closed -$434 – 4684
2025
Q4 		$434 Buy
+12,400
New +$1.25K ﹤0.01% 3862

Other funds holding LIMNW

AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Point72 Asset Management's LIMNW Position: Q1 2026 in Review

Point72 Asset Management sold out of Liminatus Pharma Warrants (LIMNW) in Q1 2026, closing a stake of 12,400 shares — an estimated $434 sold.

Point72 Asset Management first reported a position in LIMNW in Q4 2025 and held it in 1 quarter. The position peaked at $434 in Q4 2025. 21 funds tracked by Wall St. Rank hold LIMNW as of Q1 2026.

  • Point72 Asset Management reported no remaining Liminatus Pharma Warrants position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 12,400 Liminatus Pharma Warrants shares in Q1 2026, an estimated $434.
  • Point72 Asset Management first reported a position in Liminatus Pharma Warrants in Q4 2025 and held it in 1 quarter.
  • Point72 Asset Management's Liminatus Pharma Warrants position peaked at $434 in Q4 2025.
  • 21 funds tracked by Wall St. Rank held Liminatus Pharma Warrants as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.